학술논문
186TiP An open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
Document Type
Abstract
Author
Source
In Journal of Thoracic Oncology April 2021 16(4) Supplement:S798-S799
Subject
Language
ISSN
1556-0864